Disclosure: SCYNEXIS, Inc. (Employee, Shareholder)
Katyna Borroto-Esoda is an Infectious Diseases Consultant with 30 years of experience in clinical and pre-clinical development of anti-infective compounds. She has provided scientific direction to antiviral, antimicrobial and antifungal programs to support the pre-clinical and clinical development of drug candidates in preparation of IND and NDA filings.
As a Research Scientist and Director, (Burroughs Wellcome/Glaxo Wellcome, Triangle Pharmaceutical/Gilead Scynexis) she established and sustained external collaborations with academic leaders to support research projects in HIV, HCV, HBV, and antifungals and has facilitated and presented scientific presentations to physicians and providers in support of marketing activities for approved compounds.
As a consultant, Katyna directed the preclinical programs and established an extensive network of academic collaborators in order to expand the research objectives of small and midsize start up companies. In addition, she has provided scientific expertise to the clinical virology/microbiology programs for the development of novel antivirals (influenza and SARS CoV-2) and antifungals. Her experience working with multi-disciplinary teams while in industry is an asset that has enabled her to move to new projects in a seamless manner.
Katyna has an MS degree in Biochemistry from the University of Georgia and serves on advisory boards for North Carolina State University. She has been active as a member of the American Society for Microbiology, the International Society of Antiviral Research, the European Association for the Study of Liver diseases and the Mycosis Study Group.